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Alterations in glycosphingolipid (GSL) production results in lysosomal storage disorders
associated with neurodegenerative changes. In Gaucher’s disease, the patients also
develop osteoporosis that is ameliorated upon treatment for the underlying defect in GSL
metabolism. The role of GSLs in osteoclast and osteoblast formation is discussed here as
well as the potential therapeutic uses of already approved drugs that limit GSL production
in bone loss disorders such as multiple myeloma and periodontal disease.
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INTRODUCTION
Endocrine disorders such as Cushing’s syndrome and hyperthy-
roidism are well known for their deleterious effects on bone
density (Walker-Bone, 2012). Disorders with chronic inﬂamma-
tion such as rheumatoid arthritis and inﬂammatory bowel disease
also present with systemic bone loss (Miazgowski et al., 2012).
However, the importance of osteoporosis in some patients can be
overlooked due to more immediate health concerns. It may be
seen as a secondary complication attributed to treatment regime,
such as long-term glucocorticoid use, whereas it may in fact be
telling us more about a direct effect of the primary pathology on
bone homeostasis. In lysosomal storage disorders (LSDs), such
as Gaucher’s disease, patients present with osteoporotic bone
loss, in addition to characteristic hematological and neurological
defects, that improves with treatment for the underlying defect in
glycosphingolipid (GSL) metabolism. Clinical observations show
that enzyme replacement therapy (ERT) affects favorably not just
the nervous system but also ameliorates the reduction in bone
mineral density and consequent osteoporosis (El-Beshlawy et al.,
2006; Pastores et al., 2007).
WHAT ARE GLYCOSPHINGOLIPIDS?
Sphingolipids and their glycosylated derivatives, GSLs constitute
a diverse array of lipids in which a ceramide lipid backbone
is linked to one or more saccharides (Fyrst and Saba, 2010;
Kolter, 2011).
Sphingolipids contain a sphingoid base (sphingosine in mam-
malian cells) that by acylation with a fatty acid results in a
ceramide moiety as their core; the addition of a phospho-
choline head group generates sphingomyelin, while the addition
of sugars to the ceramide moiety generates GSLs (Figure 1).
When the head group contains the negatively charged sugar
sialic acid, the GSL are referred to as gangliosides, whereas
when they lack sialic acid, they are called neutral GSL. The
complex processes of biosynthesis and degradation of sphin-
golipids and GSL involve numerous enzymes located in various
subcellular compartments. The de novo biosynthesis of GSLs is
initiated at the cytoplasmic face of the endoplasmic reticulum
(ER) by serine and palmitoyl-CoA condensation that ultimately
generates ceramide. Conversion of ceramide to glucosylceramide
(GlcCer) by glucosylceramide synthase (GCS) is a critical and
rate limiting biochemical step in GSL biosynthesis (Ichikawa and
Hirabayashi, 1998; Fyrst and Saba, 2010; Xu et al., 2010). Sub-
sequently, GlcCer is converted to lactosylceramide (LacCer) by
β-(1,4) transfer of galactose from UDP-galactose by galactosyl-
transferase I (Nomura et al., 1998). LacCer provides the common
substrate for the synthesis of more complex GSL (Huwiler et al.,
2000). The stepwise conversion of LacCer to the mono-, di-,
and trisialo-gangliosides (GM3, GD3, and GT3, respectively)
involving the sequential activities of sialyltransferases and gly-
cosyltransferases in turn gives rise to the precursors for the
synthesis of the o-, a-, b-, and c-series of GSL with none, one,
two, or three sialic residues attached to the 3-position of the
galactose residue of LacCer (Lahiri and Futerman, 2007; Fuller,
2010; Figure 1). After their biosynthesis, GSLs are transported
by exocytosis to the plasma membrane in which they integrate.
Besides de novo biosynthesis, GSL can also be formed bymetabolic
recycling of the building blocks (such as monosaccharides, sphin-
gosine, and ceramide) released in their catabolic degradation. This
recycling of catabolic degradation products for biosynthetic pur-
poses is known as metabolic salvage pathway (Tettamanti, 2003;
Tettamanti et al., 2003).
Constitutive degradation of GSLs takes place in endosomes
and lysosomes. Together with othermembrane components, GSLs
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FIGURE 1 | Schematic view of the GSL de novo biosynthesis pathway.
Ceramide, the metabolic precursor of complex sphingolipids, occupies a
central position in the GSL biosynthesis. Ceramide synthesis occurs in the
ER, while at the level of cis-Golgi apparatus GlcCer is generated that is
converted in LacCer in the trans-Golgi. The reactions involving ceramide
transformation into all major classes of GSL are catalyzed in the lumen
of the Golgi apparatus by membrane-bound transferases. Ceramide
glucosyltransferase (GCT), also known as glucosylceramide synthase (GCS),
is the rate limiting step for the synthesis of all major classes of GSL. GSL
inhibitors like NB-DNJ inhibit GCS and hence the biosynthesis of all major
GSL. Dashed line: intermediate synthesis steps are not shown. Sphingolipids
synthesized in the ER are in red and in a box; GSL synthesized in the
Golgi are in black. The GSL synthesis rate limiting enzyme GCS is shown
in italics.
enter the acidic compartment via endocytosis and their terminal
carbohydrate residues are sequentially cleaved off by lysosomal
glucosidases obtaining ceramide which can then leave the lyso-
some to be recycled together with other cleavage products within
the mentioned salvage pathways or be further degraded (Sandhoff
and Kolter, 2003; Kolter, 2011). In the non-lysosomal degradation
process throughout different subcellular localizations, ceramide is
subsequently degraded to sphingosine and a fatty acid by the action
of a family of ceramidases (Hannun and Obeid, 2002; Sandhoff
and Kolter, 2003; Kolter and Sandhoff, 2005).
Although sphingolipids and GSL are a minor component of
the total cellular lipid pool (5–10%), their accumulation in certain
cell types forms the basis of many diseases (Butters, 2007a; Kolter,
2011). Biosynthesis and degradation of these lipids is closely reg-
ulated by numerous enzymes, and the failure of a given enzyme
to participate in the metabolism results in the accumulation of
the enzyme’s substrate, giving rise to lysosomal storage diseases.
Defective GSL catabolism and degradation characterizes a group
of LSDcalled the glycosphingolipidoses (see below; Butters, 2007b;
Fuller, 2010; Cox and Cachon-Gonzalez, 2012).
GSL IN PHYSIOLOGY AND DISEASE
Glycosphingolipid, constituents primarily of the outer leaﬂet of
the cellular plasma membrane, vary between different tissues and
during cell differentiation. This variability reﬂects their differing
functional roles in many cellular processes including modiﬁcation
of cell signaling initiated by tyrosine kinases at the cell membrane,
cell cycle control and apoptosis, adhesion, and migration (Kolter
and Sandhoff, 2006). While, at the single-cell level and in in vitro
cultures, GSL are not essential for cell survival or even differ-
entiation, embryonic lethality of GCS knockout mice suggests
that they are critical for cellular processes at the multicellular
whole-organism level (Yamashita et al., 1999).
Glycosphingolipidoses are rare autosomal recessive disorders
characterized by defects in GSL catabolism and accumulation of
GSL substrates in lysosomes. These include GM1-gangliosidosis,
GM2-gangliosidosis, Tay-Sachs, Krabbe, Fabry, Sandhoff, Far-
ber, Niemann–Pick, and three subtypes of Gaucher’s disease
(Kolter and Sandhoff, 2006) with type I being by far the most
common (Hughes et al., 2007). Gaucher’s disease is caused by
partial or severe deﬁciency of lysosomal β-glucocerebrosidase,
resulting in accumulation primarily of N-acyl-sphingosyl-1-O-
β-D-glucoside. In type I Gaucher’s disease, partial deﬁciency of
glucocerebrosidase is associated with the accumulation of GSL
in macrophages resulting in a distinctive morphology (Gaucher’s
cells). These cells are present in the liver, bone marrow, and
spleen leading to the clinical manifestations of massive hep-
atosplenomegaly and bone marrow failure with peripheral blood
cytopenias. Type II and III Gaucher’s disease are addition-
ally characterized by variable neurological abnormalities and
an overall worse prognosis than type I. Furthermore, patients
with Gaucher’s disease develop progressive osteoporosis and
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often osteolytic lesions, believed to reﬂect increased osteoclastic
activity.
In addition to ERT, a useful and effective treatment option
for Gaucher’s disease and other glycosphingolipidoses is sub-
strate reduction therapy (SRT). This is aimed at depleting GSL
biosynthesis via inhibition of key enzyme ceramide-speciﬁc glu-
cosyltransferase (Figure 1) by N-alkylated imino sugars, e.g.,
N-butyldeoxynojirimycin (NB-DNJ; Miglustat) or N-butylde-
oxygalactonojirimycin (NB-DGJ; Butters et al., 2005). However,
the glucose analog, NB-DNJ, is also an inhibitor of intestinal and
ER α-glucosidases, and can lead to bowel irritation in man.
In Gaucher’s disease, the inﬁltration of the bone marrow by
glucocerebroside-laden macrophages triggers a diverse pattern of
skeletal disease that results in crippling complications, including
osteoporosis. The severity and pattern of skeletal disease deter-
mines disease status and the response to SRT (Butters, 2007a).
Notably, NB-DNJ has been shown to signiﬁcantly improve osteo-
porosis (bone mineral density) and associated clinical manifesta-
tions (e.g., bone pain, risk of a vascular necrosis, and fractures) in
patients with Gaucher’s disease (El-Beshlawy et al., 2006; Pastores
et al., 2007). This salutary effect is probably linked to the relatively
selective uptake of NB-DNJ by cells of the macrophage lineage
to which the osteoclast belongs. Bone involvement in other gly-
cosphingolipidoses is less well described. In an animal model of
Krabbe disease, the femora of twitcher mice are smaller than of
those of wild type mice, and present with abnormality of marrow
cellularity, bone deposition (osteoblastic function), and osteoclas-
tic activity (Contreras et al., 2010). A mouse model emulating
type I Gaucher’s disease has been created by the conditional dele-
tion of the glucocerebrosidase gene (GBA1) in the hematopoietic
and mesenchymal cell lineages using the Mx1 promoter. Analysis
of these mouse revealed that they fully recapitulated the human
disease in terms of cytokine measurements, microarray analy-
sis, and cellular immunophenotyping. Additionally, there was
widespread dysfunction of macrophages, thymic T cells, dendritic
cells, andosteoblasts leading to adramatic loss of bone architecture
(Mistry et al., 2010).
In cancers, alterations in the cellular GSL proﬁle have long
been recognized as a trait of malignant transformation (Hako-
mori, 2001). Surface-bound as well as shed GSL have been
shown to modulate cellular functions that promote tumor sur-
vival and growth, metastasis, and angiogenesis (Hakomori, 2001;
Birkle et al., 2003). In acute myeloid leukemia (AML) patients
there is higher expression of the GSL lactotriaosylceramide (Lc3),
GM3, and neolactotetraosylceramide (nLc4) in the bone mar-
row compared to healthy donors. It is thought that these GSL
may be involved in the initiation and differentiation of AML
(Wang et al., 2012). Oncogene-transformed ﬁbroblasts from GM3
synthase/GM2 synthase double knockout mice are not able to
form complex gangliosides and displayed signiﬁcantly impaired
tumor growth in syngeneic immunocompetent mice, under-
scoring the pivotal role of tumor cell-derived gangliosides (Liu
et al., 2010).
GLYCOSPHINGOLIPIDS AND LIPID RAFT FORMATION
Together with glycerophospholipids and cholesterol, GSL are
building blocks of eukaryotic membranes. On the surface of
mammalian cells GSL are not homogenously distributed but form
patterns that are characteristic of the cell type, and alter in response
to cell growth, differentiation, oncogenesis, and external stimuli.
Along with sphingomyelin and cholesterol, GSL form membrane
microdomains known as lipid rafts (Simons and Ikonen, 1997;
Pike, 2006). These are transient dynamic, detergent-insoluble
structures (Eggeling et al., 2009) in which nascent interactions
between GSL and different receptor proteins are essential for
initiating a variety of signaling cascades.
Membrane lipid rafts play a key role in immune cell activa-
tion by recruiting and excluding speciﬁc signaling components
of immune cell surface receptors upon receptor engagement. Sig-
naling through lipid raft associated GSL activity was shown to
be important in many cell types including osteoclasts (Ha et al.,
2003b). The ganglioside GM1, also known as a GSL-enriched
microdomain (GEM) marker, is invariably associated with these
structures. Of the hundreds of differentGSL species present in bio-
logical membranes, lipid raft biophysical studies havemainly been
performed with only a few representative species. These include,
e.g., gangliosides GM3 and GM1, LacCer, sulfatides, and the small
neutral monoglycosylceramides (GlcCer and GalCer; Westerlund
and Slotte, 2009). Studies indicate that variations in the particular
GSLs present in lipid rafts determines cellular signaling capacity
(Pike, 2006).
GLYCOSPHINGOLIPIDS, LIPID RAFTS, AND OSTEOCLASTOGENESIS
Osteoclasts, the bone resorbing cells, form by the fusion of
mononuclear precursors in the presence of two major pro-
osteoclastogenic cytokines, receptor activator of NF-κB ligand
(RANKL), a surface-bound or soluble cytokine, and macrophage-
colony stimulating factor (M-CSF; Horwood et al., 1998; Hsu
et al., 1999; Kong et al., 1999). Osteoclast formation and activa-
tion can be further enhanced via the combination of these factors
with inﬂammatory cytokines and growth factors present in disease
(Horwood, 2008). The role of GSLs in osteoclast development and
activity is an area of on-going research.
Previous work has shown that LacCer, GM2, and GM3 are
the main GSL constituents of mature osteoclasts (Iwamoto et al.,
2001) while GM1 co-localizes with RANK, the RANKL receptor,
in lipid rafts (Ha et al., 2003b). Inhibition of GSL synthesis by the
non-speciﬁc GCS inhibitor D-threo-1-phenyl-2-decanoylamino-
3-morpholino-1-propanol (D-PDMP; Iwamoto et al., 2001) or
chemical disruption of lipid rafts prevents RANKL driven osteo-
clast development (Ha et al., 2003b): the expression of RANK was
reducedmarkedly in D-PDMP-treated cells. An in vitro synergistic
effect of exogenous LacCer in RANKL-dependent osteoclastoge-
nesis was also shown. Exogenous GM3 and GM1 was able to
restore osteoclast formation but to a lesser extent than LacCer
(Iwamoto et al., 2001). Likewise, we have shown that GM3 is a pro-
osteoclastogenic factor that synergistically enhances the ability of
the pro-osteoclastogenic factors RANKL and insulin-like growth
factor-1 (IGF-1) to induce the maturation of osteoclasts. Inhi-
bition of GSL synthesis using the imino sugar NB-DNJ, a more
speciﬁc GCS inhibitor, dramatically inhibited RANKL-induced
osteoclastogenesis (Xu et al., 2009).
Lipid rafts are essential for osteoclast development and acti-
vation as shown by the ﬁnding that cholesterol depletion by
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methyl-β-cyclodextrin impairs the rufﬂed border-targeted vesi-
cle trafﬁcking pathway and bone resorption (Mulari et al., 2008).
Consistentwith a role of rafts in osteoclast activation, the raft com-
ponent ﬂotillin greatly increased during osteoclast differentiation.
Recent investigations oriented toward elucidating the effects of
GSL synthesis inhibitors in osteoclast development and function
proposed that these compounds are able to regulate osteoclastoge-
nesis by interfering with RANK, c-Src and TRAF6 co-localization
in the lipid raft, thereby ultimately interfering with the signaling
cascade that activates theNF-κBpathway and the subsequent tran-
scription of osteoclastogenic genes (Ha et al., 2003a; Fukumoto
et al., 2006). Proximal signaling events following engagement of
RANK by RANKL includes translocation of TRAF6 to rafts where
Src is constitutively resident. Disruption of rafts by GSL inhibitors
blocked TRAF6 translocation and Akt activation in response
RANKL and further reduced the survival and actin ring formation
of osteoclasts (Ha et al., 2003b).
Bahtiar et al. (2009) identiﬁed the amino acid L-Ser in the dif-
ferentiation medium as necessary for the expression of NFAT2, a
transcription factor critical for osteoclast activation and function.
Serine analogs that antagonize the function of L-Ser suppressed the
formation of osteoclasts in bone marrow as well as the expression
and localization of RANK in membrane lipid rafts; the addition
of LacCer rescued the osteoclastic formation. When adminis-
tered in vivo, the analog signiﬁcantly increased bone density
in mice and prevented high bone turnover induced by treat-
ment with soluble RANKL (Bahtiar et al., 2009). The impact
on other GSLs was not investigated but given our ﬁndings and
those of others it is likely that GM3 would also be able to res-
cue osteoclast activity. Since L-Ser is required for formation of
ceramide and ultimately of GSL (see Figure 1), an interesting
possibility, compatible with the ability of LacCer to rescue the
inhibitory effect of Ser analogs, is that the pro-osteoclastogenic
effect of L-Ser is mediated through increased biosynthesis and
presence of GSL in lipid rafts, promoting RANKL-dependent
signaling.
GLYCOSPHINGOLIPIDS AND OSTEOBLAST DEVELOPMENT
Much less is known regarding the role of GSL on the develop-
ment of osteoblasts, the bone forming cells that in concert with
osteoclasts are responsible for bone remodeling and homeostasis.
Inhibition of ST3 β-galactoside α-2, 3-sialyltransferase 2 (ST3Gal
II), the enzyme required for ganglioside GD1a synthesis (Figure 1)
resulted in reduced osteoblast differentiation as measured by
alkaline phosphatase levels. This was due to reduced phos-
phorylation of extracellular signal-regulated kinases (ERK) 1/2
mitogen-activated protein (MAP) kinase and epidermal growth
factor receptor (EGFR; Yang et al., 2011). High-performance thin-
layer chromatography of human mesenchymal stem cells (MSCs)
showed that ganglioside GM3 expression was decreased, whereas
ganglioside GD1a expression was increased during the differen-
tiation of MSCs into osteoblasts. Furthermore, treatment with
GM3 reduced alkaline phosphatase production by osteoblasts and
reduced EGFR phosphorylation (Kim et al., 2008). More recently,
in the GBA1 conditional deletionmice, a defect in osteoblast activ-
ity in vitro and in vivo was discovered. This resulted in severe
osteoporosis due to a defect in osteoblastic bone formation arising
from an inhibitory effect of the accumulated lipids (LysoGL-1 and
GL-1) on protein kinase C activity (Mistry et al., 2010).
Taken together with the effects of GM3 on osteoclastogene-
sis, this would suggest that increasing levels of GM3, as seen in
multiple myeloma (MM) patients (see below), would be indica-
tive of bone loss due to excessive osteoclast activity and a failure
of osteoblast activity. Further investigation of other bone loss
disorders and their GSL proﬁles remains to be completed.
THERAPEUTIC POSSIBILITIES TARGETING
GLYCOSPHINGOLIPID PRODUCTION IN BONE DISEASES
BONE DISEASE IN GAUCHER’S DISEASE
While ERT and SRT clearly beneﬁt on bone disease and osteo-
porosis in patients with Gaucher’s disease, the exact cellular and
molecular basis of bone disease in these patients are not fully
understood.
Increased levels of cathepsin K, the cysteine protease secreted
by activated osteoclasts and responsible for organic bone degra-
dation, have been reported in the serum and spleens of patients
with Gaucher’s disease (Moran et al., 2000). Whether this reﬂects
increased frequency and activity of osteoclasts has not been studied
directly either in patients or animal models of Gaucher’s dis-
ease. In addition, the pro-inﬂammatory milieu associated with
Gaucher’s disease, and in particular the elevated levels of the pre-
osteoclastogenic cytokines interleukin (IL)-1, IL-6, and tumor
necrosis factor-α (TNF-α) secreted by pathological macrophages,
might be another important parameter in the pathogenesis of bone
disease in these patients (de Fost et al., 2008).
Given the tightly regulated cross-talk between osteoclasts and
osteoblasts, osteoblast function is likely to be altered in Gaucher’s
disease. This has been conﬁrmed in the GBA1 conditional dele-
tion mice (Mistry et al., 2010). Although direct evidence of this is
lacking in humans, analysis of the cellular biochemistry of MSCs
from an adult patient with Gaucher’s disease type I (N370S/L444P
mutations), showed that Gaucher’s MSCs have a marked increase
in COX-2, prostaglandin E2, IL-8, and CCL2 production com-
pared with normal controls (Campeau et al., 2009). Additionally,
Lecourt et al. (2012) have used an in vitro chemical model of GBA
depletion with Conduritol B Epoxide (CBE), a speciﬁc inhibitor
of GBA activity, to assess capacity of bone marrow MSC to differ-
entiate in to osteoblasts. They observed a dramatic impairment of
MSCs proliferation and although the capacity of MSCs to differ-
entiate into osteoblasts was not altered, the expression of IL-6,
IL-8, monocyte chemoattractant protein-1 (MCP1), dickkopf-
1 (DKK1), and stromal cell-derived factor 1 (SDF1) were all
increased. Furthermore, conditioned media from CBE-treated
MSCs enhancedosteoclastic bone resorption (Lecourt et al., 2012).
The expression of RANKL and OPG by these cells has not been
investigated however it is likely given the increase in inﬂamma-
tory cytokines that these osteoclast promoting factors will be
elevated and could contribute to skeletal disease and immune dis-
ease manifestations in amanner distinct and additive to Gaucher’s
macrophages themselves.
BONE DISEASE IN MULTIPLE MYELOMA
The hematological malignancy, MM, is associated with osteolytic
bone lesions and skeletal complications in over 80% of patients
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(Roodman, 2010). Interactions betweenmyeloma cells and cells of
the bonemarrowmicroenvironment promote both tumor growth
and survival and bone destruction, and the osteolytic bone dis-
ease is now recognized as a contributing component to tumor
progression. Since myeloma bone disease is associated with both
an increase in osteoclastic bone resorption and a suppression of
osteoblastic bone formation, research to date has largely focused
upon these cells. However, it is now clear that other cell types
within the bone marrow, including cells of the immune sys-
tem, MSCs and bone marrow stromal cells, can contribute to the
development of myeloma bone disease (Fowler et al., 2011).
Osteolytic lesions are localized to areas adjacent to tumor
growth and are characterized by increased activity of osteoclasts
and suppression of osteoblastogenesis (Roodman, 2010). Direct
interaction of MM plasma cells with bone marrow stromal cells
and osteoblasts is the trigger for the production of a number of
cytokines, such as IL-6, that act in an auto- or paracrine fashion
to promote survival and growth of the tumor itself and increase
osteoclast activity resulting in bone loss (Podar et al., 2009). The
activation of osteoclasts in MM is thought to occur in response to
osteoclast activating factors including RANKL and IGF-1. Despite
different current clinical strategies to stoposteoclast activation that
include myeloma-speciﬁc therapy such as bortezomib, or treat-
ment speciﬁc to osteoclasts such as bisphosphonates, bone disease
remains a serious clinical problem (Zangari et al., 2012).
Earlier work on the glycolipid proﬁle of myeloma cell lines
showed increased expression of gangliosides GM2 and GM3 and
of the neutral GSL LacCer and globosides Gb3 and Gb4 (Kalisiak
et al., 1991; O’Boyle et al., 1996). This combination of increased
production of speciﬁc GSL along with osteoclastogenic cytokine
production would lead to dramatically enhance osteoclast forma-
tion and consequent bone destruction. It is possible that inhibition
of de novoGSL synthesis in osteoclasts byN-alkylated imino sugars
like Miglustat would reduce both osteoclast formation and tumor
growth, either alone or in combination therapy with the protea-
some inhibitor, bortezomib, and other established anti-myeloma
agents. This combination would thus treat both the bone dis-
ease and the problem of MM cells failing to undergo appropriate
apoptosis.
An interesting link between myeloma and Gaucher’s disease
exists: patients with Gaucher’s disease have a 6–50 times increased
risk of developing myeloma as well as of the pre-myeloma
condition monoclonal gammopathy of uncertain signiﬁcance
(Rosenbloom et al., 2009). Although increased secretion of IL-6,
a cytokine critical for myeloma survival, by the pathological
Gaucher’s disease macrophages might play an important role,
the complete pathogenetic basis of increased risk of myeloma
in Gaucher’s disease remains to be elucidated. Nevertheless, this
unique relationship between Gaucher’s disease and myeloma fur-
ther underscores the role of GSL in osteoclastogenesis and the
potential of imino sugar inhibitors as treatment for osteoclastic
bone disease.
BONE LOSS IN PERIODONTAL DISEASE
Lipopolysaccharide (LPS) and lipid A, lipoprotein, ﬁmbriae, and
phosphorylated dihydroceramides of Porphyromonas gingivalis
have been reported to lead to osteoclast modulation and alve-
olar bone loss via TLR2 interaction. Both the LPS and lipid
A derived from P. gingivalis are contaminated with phosphory-
lated dihydroceramide lipids and the proportion of these lipids
increases with disease suggesting that TLR2 activation of host
tissues attributed to LPS and lipid A of P. gingivalis could actu-
ally be mediated by phosphorylated dihydroceramides (Nichols
et al., 2012). Furthermore, P. gingivalis lipids have been reported
to inhibit osteoblast function and gene expression (Wang et al.,
2010). Conversely, ceramide signaling has been reported to stim-
ulate osteoblast survival and apoptosis; this effect of ceramide
on cell viability was speciﬁc as C(2)-dihydroceramide had no
effect. The authors propose that alteration in the intracellular
levels of ceramide may be important in bone remodeling (Hill
and Tumber, 2010). Thus in periodontal disease, the elevated lev-
els of phosphorylated dihydroceramides will promote osteoclast
function whilst inhibiting osteoblast function leading to net bone
loss. Using patients with treatment resistant periapical lesions,
the relative proportions of GSL have been determined showing
an increase in the presence of GM3 (Zuolo et al., 2001). Thus
alteration in GSL synthesis and the presence of bacterially derived
lipids leads to the activation of osteoclasts and the inhibition of
osteoblasts. In combination with elevated inﬂammatory cytokine
production this will lead to the consequent bone depletion and
tooth loss.
FUTURE DIRECTIONS
The characterization of GSLs in bone tumors, such as giant cell
tumor of bone and the various osteosarcomas, remains to be
described. The reversal of osteoporosis in Gaucher’s patients fol-
lowing treatment for their LSD combined with the direct effects
of ganglioside GM3 on osteoclastogenesis and the alterations in
GSLs observed in other diseases suggests that targeting GSLs may
improve osteoclastic bone loss. The effectiveness of targeting GSL
in patients with osteoporosis that is not a result of LSD requires
further investigation. Likewise the role of GSLs in osteoblast for-
mation and activation is an exciting area for future bone anabolic
therapies.
The sheer number and diversity of GSLs and related molecules
makes this ﬁeld of research an extremely challenging one. How-
ever, all the signs are showing that modifying the expression levels
of GSLs may be therapeutically beneﬁcial, not just for patients
with Gaucher’s disease but also for cancer and inﬂammation-
associated bone loss. The fact that imino sugar inhibitors,
such as Miglustat (NB-DNJ), have been used therapeutically
in patients with Gaucher’s disease (Butters, 2007b) provides
an approved drug along with safety proﬁle information that
would allow swift application of these inhibitors to bone loss
diseases.
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